ES2401904R1 - RECOMBINING VECTORS BASED ON THE MODIFIED VIRUS OF ANKARA (MVA), WITH DELETION IN THE GEN C6L, AS VACCINES AGAINST HIV / AIDS AND OTHER DISEASES. - Google Patents
RECOMBINING VECTORS BASED ON THE MODIFIED VIRUS OF ANKARA (MVA), WITH DELETION IN THE GEN C6L, AS VACCINES AGAINST HIV / AIDS AND OTHER DISEASES.Info
- Publication number
- ES2401904R1 ES2401904R1 ES201131230A ES201131230A ES2401904R1 ES 2401904 R1 ES2401904 R1 ES 2401904R1 ES 201131230 A ES201131230 A ES 201131230A ES 201131230 A ES201131230 A ES 201131230A ES 2401904 R1 ES2401904 R1 ES 2401904R1
- Authority
- ES
- Spain
- Prior art keywords
- mva
- aids
- diseases
- vaccines against
- against hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Vectores recombinantes basados en el virus modificado de Ankara (MVA), con deleción en el gen C6L, como vacunas contra el VIH/SIDA y otras enfermedades. La presente invención se engloba dentro de los campos de la biología molecular y de la biotecnología. Específicamente se refiere a virus recombinantes basados en el virus modificado de Ankara (MVA) que expresan los antígenos gp120 y Gag-Pol-Nef del virus de la inmunodeficiencia humana (VIH-1) de subtipo B (MVA-B), sobre los que se ha delecionado el gen de vaccinia C6L, y que han sido diseñados para utilizarse como vacunas contra el VIH/SIDA y otras enfermedades.Recombinant vectors based on the modified Ankara virus (MVA), with deletion in the C6L gene, as vaccines against HIV / AIDS and other diseases. The present invention falls within the fields of molecular biology and biotechnology. Specifically it refers to recombinant viruses based on the modified Ankara virus (MVA) that express the gp120 and Gag-Pol-Nef antigens of the human immunodeficiency virus (HIV-1) of subtype B (MVA-B), on which The C6L vaccinia gene has been deleted, and they have been designed to be used as vaccines against HIV / AIDS and other diseases.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201131230A ES2401904B1 (en) | 2011-07-19 | 2011-07-19 | RECOMBINANT VECTORS BASED ON THE MODIFIED VIRUS OF ANKARA (MVA), WITH DELETION IN THE C6L GEN, AS VACCINES AGAINST HIV / AIDS AND OTHER DISEASES. |
PCT/ES2012/070521 WO2013011179A2 (en) | 2011-07-19 | 2012-07-11 | Recombinant vectors based on the modified vaccinia ankara (mva) virus, with deletion in the c6l gene, as vaccines against hiv/aids and other diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201131230A ES2401904B1 (en) | 2011-07-19 | 2011-07-19 | RECOMBINANT VECTORS BASED ON THE MODIFIED VIRUS OF ANKARA (MVA), WITH DELETION IN THE C6L GEN, AS VACCINES AGAINST HIV / AIDS AND OTHER DISEASES. |
Publications (3)
Publication Number | Publication Date |
---|---|
ES2401904A2 ES2401904A2 (en) | 2013-04-25 |
ES2401904R1 true ES2401904R1 (en) | 2013-06-05 |
ES2401904B1 ES2401904B1 (en) | 2014-04-07 |
Family
ID=47558548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES201131230A Expired - Fee Related ES2401904B1 (en) | 2011-07-19 | 2011-07-19 | RECOMBINANT VECTORS BASED ON THE MODIFIED VIRUS OF ANKARA (MVA), WITH DELETION IN THE C6L GEN, AS VACCINES AGAINST HIV / AIDS AND OTHER DISEASES. |
Country Status (2)
Country | Link |
---|---|
ES (1) | ES2401904B1 (en) |
WO (1) | WO2013011179A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016086980A1 (en) * | 2014-12-02 | 2016-06-09 | Consejo Superior De Investigaciones Cientificas | Vaccine composition |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001085932A2 (en) * | 2000-05-10 | 2001-11-15 | Aventis Pasteur Limited | Immunogenic polypeptides encoded by mage minigenes and uses thereof |
WO2010127115A1 (en) * | 2009-04-30 | 2010-11-04 | Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) | Modified immunization vectors |
-
2011
- 2011-07-19 ES ES201131230A patent/ES2401904B1/en not_active Expired - Fee Related
-
2012
- 2012-07-11 WO PCT/ES2012/070521 patent/WO2013011179A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001085932A2 (en) * | 2000-05-10 | 2001-11-15 | Aventis Pasteur Limited | Immunogenic polypeptides encoded by mage minigenes and uses thereof |
WO2010127115A1 (en) * | 2009-04-30 | 2010-11-04 | Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) | Modified immunization vectors |
Non-Patent Citations (3)
Title |
---|
GARCÍA-ARRIAZA, J. et al. Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions. PLoS One. Agosto 2010, Vol. 5, Nº 8, Nº artículo: e12395. ISSN 1932-6203. * |
GONZÁLEZ, J. M. et al. A poxvirus Bcl-2-like gene family involved in regulation of host immune response: sequence similarity and evolutionary history. Virology Journal. Marzo 2010, Vol. 7, Nº 1, Nº artículo: 59. ISSN 1743-422X. * |
GUERRA, S. et al. Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS. Journal of Virology. Agosto 2010, Vol. 84, Nº 16, páginas: 8141 - 8152. ISSN 1098-5514. * |
Also Published As
Publication number | Publication date |
---|---|
WO2013011179A2 (en) | 2013-01-24 |
WO2013011179A3 (en) | 2013-03-14 |
ES2401904B1 (en) | 2014-04-07 |
ES2401904A2 (en) | 2013-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018006706A2 (en) | Mutated viruses, method of preparation and use thereof | |
BR112018008090A2 (en) | herpes simplex virus vaccine. | |
CL2017000780A1 (en) | Compositions and methods to silence the expression of the hepatitis b gene virus | |
EA201591287A1 (en) | VACCINES CONTAINING STABILIZED TRIMMERS OF THE HUMAN IMMUNODEFICIENCY VIRUS VIRUS, AND METHODS OF THEIR USE | |
EA201891186A1 (en) | ANTIBODIES, NEUTRALIZING THE VIRUS OF HUMAN IMMUNODEFICIENCY | |
CL2018000432A1 (en) | Therapeutic vaccines against hpv18 | |
MA44059B1 (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
GT201500020A (en) | SULFAMOILARILAMIDAS AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B | |
BR112016020688A2 (en) | COMPOSITIONS USEFUL IN THE TREATMENT OF ORNITHINE TRANSCARBAMYLASE DEFICIENCY (OTC) | |
MX2016014642A (en) | Anti-viral compounds, pharmaceutical compositions, and methods of use thereof. | |
CO2017007105A2 (en) | New tilapia viruses | |
MY173638A (en) | Parainfluenza virus 5 based vaccines | |
CU20180035A7 (en) | ATTENDED INFLUENZA VECTORS FOR THE PREVENTION AND / OR TREATMENT OF INFECTIOUS DISEASES AND FOR THE TREATMENT OF ONCOLOGICAL DISEASES | |
EA201290956A1 (en) | VACCINE AGAINST HIV | |
GT201600066A (en) | COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF GEN ALAS1 | |
CL2018001946A1 (en) | Attenuated viruses of infectious bronchitis. | |
MX2017009812A (en) | Compositions and methods for inhibiting viral infection. | |
NZ702146A (en) | Peptides derived from viral proteins for use as immunogens and dosage reactants | |
CO7461133A2 (en) | Parvovirus 5a pig, methods of use and vaccine | |
NI201700080A (en) | VACCINE COMPOSITIONS FOR DENGUE VIRUS AND METHODS OF USE OF THE SAME. | |
MX2019007924A (en) | Influenza vaccines. | |
ES2401904R1 (en) | RECOMBINING VECTORS BASED ON THE MODIFIED VIRUS OF ANKARA (MVA), WITH DELETION IN THE GEN C6L, AS VACCINES AGAINST HIV / AIDS AND OTHER DISEASES. | |
AR115070A1 (en) | STEM CELLS CONTAINING A SYNTHETIC CHIMERICAL VACCINE VIRUS AND METHODS FOR ITS USE | |
MX2015010763A (en) | H5 proteins of h5n1 influenza virus for use as a medicament. | |
CR20140432A (en) | VIRUS OF THE MODIFIED MAREK'S DISEASE AND VACCINES PREPARED WITH THE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 2401904 Country of ref document: ES Kind code of ref document: B1 Effective date: 20140407 |
|
FD2A | Announcement of lapse in spain |
Effective date: 20181015 |